Table 3 Significant canonical pathways (P <0
From: Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue
Pathway | - log10 (P) |
|---|---|
All (OB/OW versus lean) | Â |
Glycerolipid metabolism | 2.20 |
Lysine degradation | 2.08 |
Leptin signaling in obesity | 1.78 |
BPH (OB/OW versus lean) | Â |
ERK5 signaling | 2.31 |
β-alanine metabolism | 1.83 |
AMPK signaling | 1.81 |
Parkinson's signaling | 1.77 |
C21-steroid hormone metabolism | 1.77 |
EPCa (OB/OW versus lean) | Â |
Histidine metabolism | 1.91 |
Eicosanoid signaling | 1.77 |
Linoleic acid metabolism | 1.73 |
All (EPCa versus BPH) | Â |
Antigen presentation pathway | 3.11 |
Aminosugars metabolism | 2.09 |
B cell development | 1.81 |
OX40 signaling pathway | 1.77 |
ERK5 signaling | 1.59 |
p53 signaling | 1.55 |
Lean (EPCa versus BPH) | Â |
T helper cell differentiation | 2.24 |
Galactose metabolism | 1.68 |
Hereditary breast cancer signaling | 1.62 |
Role of osteoblasts, osteoclasts and condrocytes in rheumatoid arthritis | 1.51 |
OB/OW (EPCa versus BPH) | Â |
Synaptic long term depression | 2.89 |
Urea cycle and metabolism of aminogroups | 2.10 |
p53 signaling | 2.10 |
Amyothropic lateral sclerosis signaling | 2.02 |
Aminosugars metabolism | 1.89 |
Extrinsic prothrombin activation pathway | 1.73 |
p70S6K signaling | 1.68 |
Cardiac β-adrenegic signaling | 1.51 |